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Abstract
This paper shows that the conditionality of investment decisions in R&D has a crit-
ical impact on portfolio risk, and implies that traditional diversification strategies
should be reevaluated when a portfolio is constructed. Real option theory argues
that research projects have conditional or option-like risk and return properties,
and are different from unconditional projects. Although the risk of a portfolio al-
ways depends on the correlation between projects, a portfolio of conditional R&D
projects with real option characteristics has a fundamentally different risk than a
portfolio of unconditional projects. When conditional R&D projects are negatively
correlated, diversification only slightly reduces portfolio risk. When projects are pos-
itively correlated, however, diversification proves more effective than conventional
tools predict.
Key words: Real Options; Portfolio Analysis; Research & Development
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1 Introduction
When the future outcomes of a firm's endeavors are unknown, a key strat-
egy for dealing with such risk is betting on more than one horse. Successful
research and development (R&D) policy therefore requires careful portfolio
analysis to optimise the selection and the development of several concurrent
alternatives. Diversification of risk plays a key role in this process. When the
portfolio consists of risky R&D projects, however, conventional diversification
arguments do not hold since conditionality causes the payoffs to become non-
linear. This is a direct result of the option characteristics that many R&D
projects display.
Option characteristics follow from managerial flexibility to adjust decisions
under uncertainty. Any possibility of altering a project as new information
becomes available renders a project conditional. For instance, a project that
is started now may be abandoned or expanded in the future, a decision based
on a given performance criterion and usually taken when new costs need to
be incurred. As the investment decision is conditional, it can be regarded as
an `option' that is acquired by making the prior investment. We will examine
the differences between conditional and unconditional investments below, as
well as their implications for portfolio analysis.
This paper examines diversification when conditional investment decisions are
present in an R&D portfolio, and shows that reliance on traditional diversifi-
cation strategies can be misleading. Negative correlation makes diversification
a less effective instrument for eliminating risk amongst conditionally financed
Email address: vanbekkum@few.eur.nl, pennings@few.eur.nl,
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projects than for unconditional projects. Positive correlation, however, makes
diversification more effective. As compared to unconditional projects, a portfo-
lio of conditionally financed projects is less sensitive to changes in correlation
when correlation is not highly positive, and risk is therefore more difficult to
diversify. Our findings have implications for diversification strategies in port-
folio analysis. This includes (but is not limited to) the strategic choice between
a focused or diversified portfolio, diversification over time and risk measure-
ment techniques such as Value at Risk (VaR), often used in risk management
regulation.
Real options analysis has become a well-known R&D project valuation tech-
nique for intertemporal risky investments in R&D. In their seminal paper,
Black and Scholes (1973) consider equity of a real, levered firm as an option
on its entity value. Using financial theory, Myers (1977) was the first to de-
scribe real options as the opportunities to purchase real assets on possibly
favorable terms. In the strategy literature, Bowman and Hurry (1993) and
Bettis and Hitt (1995) propose real options theory as an alternative lens for
looking at technology investments that closely resemble the behaviour and
characteristics of real options. In the R&D literature, Thomke (1997) indeed
shows empirically that flexibility under uncertainty allows firms to continu-
ously adapt to change and improve products. Hartmann and Hassan (2006)
find that real options analysis is used as an auxiliary valuation tool in phar-
maceutical project valuation 1 . In this context, a basic implementation is pro-
1 The fundamental difference between real options and traditional discounted cash
flow (DCF) valuation lies in the flexibility to adapt when circumstances change.
Whereas DCF valuation assumes investments are fixed, an option is the right (not
the obligation) to invest in R&D at some future date. If future circumstances are
favourable, the option will be exercised; if not, the option will expire without any
further cost. Such freedom of choice enables an investor to abandon the project in
a timely manner so that further losses are avoided. Therefore, many unfavourable
investments (with limited downside risk) can be financed by a few highly profitable
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vided by Kellogg and Charnes (2000), and more sophisticated option valuation
models for pharmaceutical research have been developed by Loch and Bode-
Greuel (2001). Lee and Paxson (2001) view the R&D process and subsequent
discoveries as sequential (compound) exchange options. Cassimon et al. (2004)
provide an analytical model for valuing the phased development of a pharma-
ceutical R&D project. The empirical literature also confirms that R&D yields
the positively skewed distribution of returns that is typical of options. For in-
stance, Scherer & Harhoff (2000) investigated innovations and show that the
top 10% returns captured 48% to 93% of total sample returns. They refer to
Nordhaus (1989), who postulates that 99.99% of invention patents submitted
per year are worthless, but that the remaining 0.01% have high values.
In concurrence with this literature, we analyse conditionally financed projects
as options. R&D typically has a high chance of failure and can be deemed
risky. High-risk projects in R&D are generally explorative in nature; examples
include basic and fundamental research, or R&D in response to important
changes in a firm's strategic environment. We will contrast the option-like
projects to unconditional projects that typically behave similarly to equity
shares, have a low chance of failure and are subject to less risk. Low-risk
projects in R&D are often of an incremental nature; examples include `me-too'
inventions that imitate a successful competitor's invention, or investments into
an already commercialized product. We refer to the first group as conditionally
financed projects, conditional projects, or real options. We refer to the second
as unconditional projects.
Most real options studies have primarily examined projects in isolation. Eng-
investments (with unlimited upside potential). Profitable investments will account
for the majority of returns, so the return distribution becomes positively skewed.
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wall (2003), however, argues that every project takes off from, or is executed
in, an organizational context. Real options should therefore also be considered
as part of a portfolio. Brosch (2001) considers the influence of interacting real
options within projects. These positive and negative interactions between op-
tions make a portfolio's value non-additive. Our focus, however, is on option
interactions between projects, and we focus on the risk of the portfolio.
Smith and Thompson (2003, 2005) postulate a project selection strategy in
sequential petroleum exploration, where the outcome of the prior drillings can
be observed before investing in the next drilling. We are also involved with
real option selection, but focus on simultaneous (non-sequential) development.
Multiple assets have been examined by Wörner et al. (2002, 2003), who de-
scribe a firm as a `basket option' that conducts several R&D projects, or as
an option on a set of stochastic variables. Yet, as they focus on the value of a
single claim that pertains to many random variables, their analysis does not
derive results relevant to portfolio management (which inherently deals with
the selection between multiple claims). Such rainbow or basket options are
often used to describe R&D projects; Paxson (2003) surveys several real R&D
option models and utilises some of them in a case study.
When constructing an R&D portfolio, the selection of candidates comprises
many important, non-monetary considerations. For example, Prencipe and
Tell (2001) show that firms try to capture synergies that stem from learning
processes. Several studies have therefore aimed to integrate risk diversification
with expected costs and benefits, inter-project synergies, externalities, R&D
quality and overall fit with the business strategy. Taking this angle, Linton
et al. (2002) develop a framework that combines both quantitative and qual-
itative measures to rank and select the projects in a portfolio. In addition,
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Martino (1995) describes several methods for R&D project selection includ-
ing cluster analysis, cognitive modeling, simulation, portfolio optimisation,
and decision theory. While these sources are suitable for handling technical
and physical diversification, they seem less appropriate for allocating finan-
cial resources, compared to the Markowitz (1952) diversification principle.
Markowitz's objective is to optimise risk given a return, or vice versa. Chien
(2002) includes a survey of selection procedures and shows that several orig-
inated from Markowitz's work. A recent R&D selection model that is based
on that of Markowitz (1952) can be found in Ringuest et al. (2004). Unfor-
tunately, the Markowitz diversification strategy only applies when the distri-
bution of project returns is symmetric, an assumption that does not hold for
R&D projects with conditionality. Our argument supplements the Markowitz
criterion in that it explicitly considers real option characteristics; we create a
skewed distribution by simulating many real options.
Using a portfolio of two investment opportunities, we show that although
the risk of an R&D portfolio always depends on the correlation between
projects, the dependence differs between conditional projects and uncondi-
tional projects. In particular, we find that when projects are positively corre-
lated, the overall portfolio risk for conditional projects is lower than for uncon-
ditional projects. Diversification is an important argument to create a portfolio
of such projects, because it is more effective than one would expect from un-
conditional investments. In contrast, when projects are negatively correlated,
we find that the overall portfolio risk for conditional projects is higher than
for unconditional projects. Moreover, under negative correlation, portfolio risk
is less sensitive to changes in correlation as compared to unconditional invest-
ment projects. Diversification is therefore less effective than one would initially
expect from unconditional investments, and more weight should be placed on
6
non-diversification arguments to motivate a portfolio of such projects, such as
synergies and spillovers.
This paper is organized as follows: in Section 2, the theory behind a portfolio
of real options is conveyed. In Section 3 we present the model and its results.
Section 4 is dedicated to the implications of our findings. In Section 5, we
conclude and provide directions for future research. In the Appendices A and
B, a proof of our findings is provided, as well as a means to extend our analysis
to a more realistic setting.
2 Conceptual Framework
We analyze a portfolio of individual projects that await conditional invest-
ments, and represent each project by a simple call. A portfolio of calls is a
valid way to describe reality if the portfolio's constituents behave similarly to
financial options. This happens if a portfolio consists entirely of conditionally
financed projects, as is often found in pharmaceuticals, biotechnology, venture
capital and software technology.
It is important to note that we examine a portfolio of multiple contingent
claims. This differs from a single claim on several underlying stochastic pro-
cesses, such as an option on the most valuable R&D project in a portfolio. A
single claim, however, does not fit our central goal of selecting and manag-
ing multiple claims. Each individual portfolio element may well be an R&D
project or a venture facing several uncertainties and aiming for multiple mar-
kets, such that each element may be a rainbow or basket option. We study
portfolios of these elements, however, and such portfolios consist of several
claims (not their underlying values).
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The symmetry of a project's value distribution has an impact on portfolio
diversification. For unconditionally financed projects, the symmetrical distri-
bution allows for a 'perfect hedge', and a riskless portfolio can be created;
when two equity shares are perfectly negatively correlated, one goes down
by the amount that the other goes up and vice versa 2 , so that all deviation
is offset. In line with Markowitz (1952), we call this hedging mechanism the
diversification effect on the risk of a portfolio.
However, when the projects are conditionally financed, below-average results
are no longer offset by above-average returns and Markowitz's (1952) diversi-
fication principle is no longer valid. Because the payoff from a call cannot fall
below zero, an option already provides insurance against the negative payoffs
by nullifying those payoffs that are lower than the exercise price. Hence, the
value distribution of a portfolio of real call options becomes skewed from the
left and ceases to be symmetrical. The would-be-negative payoffs are no longer
available for diversification, and constructing a riskless portfolio is no longer
possible. Paradoxically, in a portfolio of options, the option to abandon limits
downside risk of the individual project, but complicates diversification and
does not limit risk when portfolio correlation is negative. In line with Jensen's
Inequality, we call this the `convexity effect', which affects the diversification
effect. In Appendix A, we derive this result as we examine the variance of a
conditionally financed portfolio more explicitly.
In the next section, we will develop a Monte Carlo simulation model to show
the effect of risky projects on a portfolio of R&D projects. The procedure is
straightforward and can easily be used in practice with other portfolio selec-
tion criteria. Before we proceed, however, a proper description of our research
2 That is, when uncertainty is constant and equal for both shares.
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subject is appropriate. This paper exclusively focuses on the risk (not the
value) of a portfolio of options, and is therefore a supplement to the previ-
ously mentioned portfolio selection criteria. Their importance notwithstand-
ing, for the sake of argument we group all these criteria under the heading
of non-diversification criteria. Uncertainty in our portfolio is completely
determined by how the value of projects varies. Portfolio variance is a well-
known measure for this dispersion, used in the financial sector under Basel
II regulations. We confine our analysis to the relation between market values
of projects, and assume the project costs to be independent and known. We
prefer this setup because modeling more than one source of uncertainty would
cause our results to become confounded. To more accurately reflect reality,
the procedure can be easily extended to accommodate two or more related
stochastic processes, such as uncertain costs and benefits.
3 Methodology and Results
3.1 Simulation Model
To find the volatility of an option portfolio, we estimate the volatility of payoffs
for each option. We model a portfolio with two projects i{1, 2}. Unless we
consider the special cases in Appendix A, it is not possible to determine the
risk of an option portfolio analytically since the joint distribution of options is
not analytically tractable. Instead, we model the behavior of both end-of-R&D
values projects Vi by a simple normal distribution, defined as follows:
Vi = µi + σiεi (1)
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where µi is the project value, σi is the standard deviation of project values
when the project is completed and εi is a random draw from a standard normal
distribution. Assuming no dividend payouts for each project i, we calculate
the option value OVi:
OVi = max[Vi −Xi, 0]e−rT (2)
where Xi is the investment needed to start or acquire the project, r is the
discount rate and T is project i's time to completion. The value of the project
can now be calculated by taking the average value of equation (2) over R
simulation rounds, with OVij representing the result of a single simulation
round for OVi. As the number of rounds increases, this value converges to its
true value. To observe how project values are distributed, the volatility of a
single option can be found as follows:
σOVi =
√√√√ 1
R
∑
j
(OVij −OVi)2 (3)
Extending to a portfolio of two projects, the relation between underlying val-
ues (not the option values) is measured by means of a correlation coefficient ρ12
between ε1 and ε2. Assuming multivariate normality, the correlation between
any number of assets can be calculated using the Cholesky decomposition.
This process, as well as constructing a consistent variance-covariance matrix
for cases where i > 2, is described in Appendix A. For the two variable case, in-
dependent samples y1 and y2 are taken from a univariate standardized normal
distribution and the correlated samples ε1 and ε2 are calculated as follows:
ε1= y1 (4)
ε2= ρ12y1 + y2
√
1− ρ212 (5)
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From one set of independent samples y1 and y2, we generate 21 pairs of corre-
lated samples ε1 and ε2 (ranging from ρ12 = −1.0 to ρ12 = 1.0 with step size
0.10) by inserting the independent sample values into equations (4) and (5).
Because, under the assumption of correlation between project values but no
interactions between the options, the value of the portfolio is the sum of the
project values i,
pf =
∑
i
OVi, (6)
the value of the portfolio can be defined for each correlation. However, we are
concerned with portfolio risk (measured by the variance of the summed option
values) rather than the value of a portfolio of options. Similar to the case for
a single option, the estimate of portfolio variance is based on a simulation of
portfolios pfj for j = 1, ..., R and averaging over R:
σˆpf=
√√√√ 1
R
∑
j
(pfj − pf)2 (7)
As a numerical example, we can show a potential simulation round using
the numbers from the bivariate base case described in Figure 1. Assume one
set of draws from the univariate distribution are the following: y1 = 0.5 and
y2 = −0.25. Using equation (5), this independent pair of draws leads to 21
correlated pairs, including (for ρ12 = −0.2)
ε1 = 0.5;
ε2:ρ=−0.2 = −0.2× 0.5− 0.25×
√
0.96 ≈ −0.34.
11
Using equation (1), if the underlying values are somewhat negatively correlated
and uncertainty is 25%, a feasible realisation would be
V1 = 20 + (25%× 20)× 0.5 = 22.5;
V2 = 20 + (25%× 20)×−0.34 = 18.3
The value of each project and the portfolio is calculated using equation (2):
OV1 = max[22.5− 25 , 0]e−rT = 0
OV2 = max[18.3− 25 , 0]e−rT = 0
pf = 0 + 0 = 0
This procedure is repeated R times for each of the 21 correlations. Of the
resulting 21 correlation-specific sets of R-sized portfolio values, we calculate
portfolio risk using the variance of the portfolio values and plot it against
the correlation. In all graphs, portfolio risk is normalized by dividing over
the summed variance of two independent calls. If we treat the two projects
as unconditional, we would have used equation (3), leading us to calculate a
`naive' portfolio variance, as described below.
3.2 Simulation Results
The curved, solid line σ2pf in Figure 1 shows the cumulative variance of 21
ρ-specific option pairs. As this paper is exclusively concerned with portfolio
risk and our results cannot be compared with other pricing methods such as
12
the seminal Black-Scholes equation 3 , no further option values are reported.
Nevertheless, values have been used in equation (7) to construct the variance,
our measure for dispersion. To illustrate the difference between the actual
portfolio risk and the calculated risk when using Markowitz diversification, we
add a dashed line σ˜2pf that shows the variance of the projects if we (wrongly)
assume Markowitz diversification to be valid. This would only be appropriate if
the separate projects are unconditional and behave as equity shares. The solid
line connects the portfolio variance for 21 different correlations and for the
dashed line, the following well-known formula to calculate portfolio variance
is used:
σ˜2pf = σ
2
OV 1 + σ
2
OV 2 + 2ρσOV 1σOV 2 (8)
Using equations (2) and (3), this line has the variance of individual option
values OV1 and OV2 as inputs for σ
2
OV 1 and σ
2
OV 2. We observe that at ρ =
0, the variance of unrelated projects is the same for both σ2pf and σ˜
2
pf . A
third, dotted line σ20 ≡ σ˜2pf :ρ=0 = σ2OV 1 + σ2OV 2 shows that the first line σ2pf
is cushioned towards a special case of σ˜2pf , which represents a portfolio of
completely unrelated options or options that are both separate and unrelated.
-
[Insert Figure 1 about here]
-
3 Our results also persist for other stochastic processes such as the geometric Brow-
nian motion, on which the Black & Scholes option pricing model is built. Under
this process, the project value's changes, instead of levels, would be normally dis-
tributed. This process is arguably more suitable for modeling skewed R&D project
values, but causes an additional asymmetry in the distribution of portfolio values.
To isolate the effects of the (also nonlinear) investment option, we choose a symmet-
rically distributed process; this makes it no longer possible to compare our results
with other models.
13
The difference lies in the interpretation of the correlation coefficient ρ that
measures the correlation between projects (the horizontal line σ20 illustrates
the degenerate case where ρ is zero). In the case of the naively calculated
variance σ˜2pf , the projects are correlated one-to-one with the projects' market
values and ρ is a constant. In the case of the correct variance σ2pf , however, co-
movement between real option projects is a function of market value and the
probability that a project is terminated 4 . This probability, in turn, depends
on the moneyness of the call options, the correlation between project values
and the volatilities of each project value. A manager who doesn't recognise
real option characteristics would end up calculating risk naively, and Figure
1 illustrates how naively calculated risk may differ from correctly simulated
risk.
In Figure 1, the naive portfolio variance at ρ = 0 is equal to the simulated
variance of the portfolio and the separate options. We also see that both σ˜2pf
and σ2pf are reduced when projects are less than perfectly positively correlated,
and that two perfectly positively correlated projects have a variance of 200%
compared to σ20, as proven in Appendix A. When the projects are negatively
correlated, both σ˜2pf and σ
2
pf are less then σ
2
0. All of these diversification effects
are in line with the theory proposed by Markovitz.
The `convexity effect', however, limits the most severe value drops but leaves
all positive development intact, so that project payoffs are non-linear and the
value distribution becomes skewed. Figure 1 and Appendix A both show that
when individual projects can no longer be offset, naively applying Markowitz
diversification may lead to significant miscalculations of risk. This is caused
4 This fact has also been used in the theoretical derivations of our results in Ap-
pendix A.
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by the interaction between the diversification and convexity effects, which has
both positive and negative consequences. When projects are positively cor-
related, the cushioning of convexity enhances diversification and overall risk
becomes lower than under Markowitz diversification. When the projects are
negatively correlated, however, the cushioning of convexity hampers the diver-
sification effect, leading to a less effective hedge. As a consequence, options are
more complex instruments for diversification than stock. In terms of the effect
that correlation has on risk, the sensitivity of unconditional risk to changes
in correlation is generally smaller than for unconditional risk, up to a cor-
relation of about ρ = 0.60. For negatively correlated projects in particular,
diversification changes the portfolio's risk only slightly. Stated more precisely,
the variance of a conditionally financed portfolio is compressed towards the
cumulative variance of two independent options. The range of a conditionally
financed portfolio is smaller than the range of an unconditional portfolio, but
the minimum is higher than the unconditional portfolio's minimum. We can
formulate the following hypotheses:
H1: For positively correlated project values, conditionally financed projects
diversify risk better than unconditional projects.
H2: For negatively correlated project values, unconditional projects diversify
risk better than conditionally financed projects.
3.3 Robustness Analysis and General Applicability
The base case (Figure 1) shows what happens when two simple and identical
options are out of the money. This setting is typical of many R&D projects.
Four panels in Figure 2 show results of simulated options that have a lower
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volatility (Panel A), a different volatility (Panel B), are at the money (Panel C)
or in the money (Panel D). In all these situations, the convexity effect persists.
Changes in other parameters such as the discount rate have no effect on the
results. In Panel A, we halve the volatility so that the project is not in the
money until the value is equal to µ+2σ. In R&D, this means that the project
is not continued in about 97.5% of the cases and hardly any of these projects
are available for risk diversification. As a consequence, the diversification effect
is nearly absent and all we see is the convexity effect; we might just as well
not diversify at all. In the less extreme case when volatilities differ, Panel
B shows that portfolio risk is less sensitive to changes in correlation than in
Figure 1 and diversification is still quite ineffective. The unit change on the
y-axis indicates that in this case, zero variance cannot be achieved by naive
calculation either. When the moneyness increases in Panel C and Panel D, the
curves move towards the straight line and our results become less distinct. This
reflects the familiar fact that deeply in the money options will behave similarly
to the underlying stock. As a consequence, the convexity effect becomes less
pronounced and the diversification effect starts to dominate. In R&D, this
means that if the value of the project is much higher then its costs, conditional
financing doesn't make a large difference because the project will be exercised
anyway.
-
[Insert Figure 2 about here]
-
Some general remarks can be made on applying our model to practice. Many
projects are funded by multiple finance or subsidy rounds and our simple calls
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represent the last phase. A more complex example involves an R&D project
that is split up into stages such that certain requirements must be met be-
fore it can enter the next development phase. This project design involves
several `compound' options, as each conditional investment is an option on
the next phase. R&D in the pharmaceutical industry, for example, is typically
characterized by six stages of development. This means that investing in the
sixth phase is conditional upon completion of the fifth phase, which requires
investments conditional on the fourth phase, etc.. These more realistic fea-
tures can easily modeled by using compound options in the simulation. In
the compounded case, we are stacking `effect on effect'. This is not demon-
strated here since such simulation results are highly dependent on the success
of entering the next round. Arbitrarily chosen input parameters (especially
for several stages) will have a critical influence on the portfolio variance and
conceal the convexity effect. Compound options can easily be put to prac-
tice by means of the closed-form model of the successive phases from R&D
to commercialization, developed Cassimon et al. (2004). Likewise, simulation
makes implementing other realistic features such as uncertain costs or time-
to-completion straightforward . That, however, would also drive us away from
the essential portfolio diversification problem.
For ease of exposition, we have limited the analysis to the smallest portfolio
possible- a portfolio of two projects. The effect is also observable when we
increase the number of assets. If we introduce a third asset and keep the
step size fixed at 0.10, for example, then 21 correlated samples are ranked
similarly for every random variable. For the 3-variable case we have a grid of
21 correlation points between variable 1 and 2, 21 between 1 and 3 and 21
between 2 and 3. Appendix B describes how a simulation procedure can be
developed for three and more projects by constructing a consistent correlation
17
structure 5 .
4 Implications
The implications of our results can be readily applied to any research policy
that concerns simultaneous development of projects, subject to conditional
financing. While various examples may illustrate this, we limit ourselves to
three: static diversification, diversification over time and capital reserve regu-
lations that protect an organization from bankruptcy.
4.1 Focus or Diversify?
An example of an application of our framework lies in resource allocation for
a geographical area, in order to effectively spur innovation. For instance, a
government may want to stimulate economic activity in a certain area. Does a
government prefer to focus business activities, in order to create a specialized
technology area such as Silicon Valley? Or would it diversify in order to prevent
overdependence on a few industries, which has proven problematic in Detroit,
an area focused on construction and car manufacturing?
Our results provide an argument based on the risk characteristics of individual
firms in both areas. Especially in an innovative field such as information tech-
nology, a start-up is often a risky business with option characteristics. This
5 At the same time, the number of possible correlations is smaller than 63. If, for
instance, two projects c1 and c2 have a negative correlation of 0.99, the third cannot
be highly correlated with both at the same time. In this three-variable case, the
correlation between c1 and c2 and a third, single option can only be defined on the
complete interval [-1, 1] when the correlation of the two projects c1 and c2 is held
constant at ρ = 0.
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is not true for construction and manufacturing. We have shown that the risk
of a group of positively correlated start-ups is lower than one would expect
if conditionality is ignored. Hence, diversification can be a good argument for
grouping innovative companies, as risk is more effectively reduced than within
industries with a more stable cash flow. Therefore, total risk in Silicon Valley
is not easily increased, even when moderate positive correlation exists between
the value drivers of the region's companies. In Detroit, however, diversification
is an important factor in the region's development.
4.2 Diversification Over Time
An important implication concerns the different effects of diversification as
the portfolio matures: when positively correlated projects are still young and
in the R&D phase, a portfolio consisting of such projects is less risky than one
would expect. But as successful projects mature, uncertainty resolves and op-
tion characteristics become less relevant, so that the same correlation between
projects leads to more diversification risk. As a result, portfolios need restruc-
turing when projects evolve and policy makers need different diversification
criteria over time. Each individual project's milestone will modify the risk
characteristics of the portfolio as a whole. To minimize overall portfolio risk,
for instance, some of the matured projects may therefore be sold in exchange
for more negatively correlated projects with low-risk.
Put differently, Figure 1 indicates that risk first develops as the curvature,
and later as the straight, dotted line. The gentle slope of the curve shows
that although the risk of positively correlated ventures is still higher than the
risk of negatively correlated ventures, the difference doesn't matter as much
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as standard portfolio theory predicts. Therefore, structuring a portfolio to
minimize variance is not as important in the early stages: non-diversification
arguments may still provide good reason to combine these projects, but risk
reduction isn't one of them. Until the projects mature and risk diminishes,
negatively correlated risky projects are less attractive portfolio candidates
for risk diversification. When ventures mature, diversification becomes more
important and the risk characteristics of positively and negatively correlated
ventures become more pronounced.
This can be observed in the pharmaceuticals sector, where many small firms
succesfully focus on a few drugs, rather than become part of a portfolio of a
large, diversified company. Why is risk diversification not necessary for small
research ventures to be successful in such a risky business? One well-known
argument is that in the early stages of development, economies of scale (for
example in marketing) are not feasible yet. Another is that the R&D process
is differently organized for small ventures than for big companies. Our re-
sults provide an additional argument for this phenomenon: under conditional
financing, a strong focus only marginally increases the risk of the portfolio
while it may strongly contribute to non-diversification criteria (such as syn-
ergies and spillovers) and preserve the upward potential. Only after several
milestones have been completed do the results of these R&D programs be-
come less uncertain, the cushioning by the convexity effect disappears and the
projects behave more like stocks. In these later stages, the risk becomes more
sensitive to changes in correlation, diversification of risk becomes important
and the venture may well be sold to a diversified company.
In this context, it may be useful to provide examples of positively and neg-
atively correlated risk. Positively correlated risk can be partially ascribed to
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non-diversifiable market risk. Another part may be ascribed to the medical
context, if projects develop drugs for `complementary treatment'. An example
is the treatment of HIV, where a combination of three drugs is prescribed;
if the side effects of one drug become less severe or effectiveness improves,
the value of all three drugs will increase, since the quality of the treatment
increases. Another example are drugs that treat closely related disorders such
as lung cancer and cardiovascular diseases. Often, both have a common cause,
such as an unhealthy lifestyle. When a patient can be treated for one illness,
he or she will live longer and odds increase that he or she will suffer from the
second illness. Ironically, this is good news for investors as the market value
of both drugs increases. An example of negatively correlated risk are two de-
velopment programs that aim to cure similar diseases; if one program yields a
major discovery, the value of the other program automatically goes down.
The problem in both examples can be described by a trade-off between focus
and diversification; when focusing, ρ > 0, and conditional portfolio risk is lower
than than standard portfolio theory might suggest because the diversification
effect is cushioned by the convex nature of options. When diversifying, ρ < 0,
and the cushioning of convexity causes diversification to be less effective than
would be expected from standard diversification arguments.
The implications of diversification over time can be summarized by the effec-
tiveness of risk management; risk diversification is not important until other
uncertainties (that justify conditional financing) have been resolved. In other
words, when an investor's risk is minimized by a milestone financing require-
ment, choosing negatively correlated projects will not diversify the risk much
further. Rather, having a strong focus is not as risky as one would expect,
and non-diversification arguments are more important selection criteria. Until
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the correlation becomes more than moderate, diversification has an insignifi-
cant effect on total risk as long as other factors justify conditional investment
decisions.
4.3 Capital Reserves
Using variance as a measure of risk lies at the basis of common financial risk
measures such as Value at Risk (VaR). Over the period that a portfolio is
held, it measures the value of the portfolio at risk that for a given confidence
interval. Similar to our `naively' constructed portfolio, the most common VaR
model assumes portfolio value to be linearly dependent on the value of the
underlying assets. In the R&D setting, however, this relationship is linear
only between portfolio value and the value of the options.
When the number of conditional projects is sufficiently large, the value of the
portfolio becomes normally distributed. If the number of conditional projects
is not sufficiently large, our results imply that the linearity assumption is inap-
propriate. To determine the VaR correctly, the variance of a portfolio should be
simulated to contruct the confidence interval. We show that the standard de-
viation is significantly higher if projects are negatively correlated, and naively
calculated variance leads to an underestimation of VaR. As an international
standard for creating capital reserves regulations, the Basel Accords may rec-
ommend simulation as a tool for risk assessment. This is true particularly for
industries in which conditional investment decisions are common practice.
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5 Conclusion and Suggestions for Future Research Di-
rections
In this article we have shown that the presence of conditional financing in R&D
may invalidates diversification strategies for portfolio construction. Under neg-
ative correlation, emphasis should be placed on other (non-diversification)
arguments when constructing a portfolio. Under positive correlation, by con-
trast, the advantages of diversification are larger than one may expect using
Markowitz diversification. We have also demonstrated that due to the con-
vexity of high-risk projects, the sensitivity of portfolio risk to correlation is
smaller for high-risk projects than for low-risk projects.
The difference in risk between high-risk and low-risk projects can be quite
substantial; for two negatively correlated risky projects of about ρ = −0.5,
the uncertainty is reduced by only 10%/50% = 20% as compared to low-
risk uncertainty reduction. For ρ = +0.5, the uncertainty is increased by
only 30%/50% = 60% as compared to low-risk uncertainty. These differences
can easily become more dramatic (Figure 2.A shows that diversification may
become impossible for negative correlations), and our findings are robust to
changes in the parameter structure of the model. We have provided examples
to show why this is important for R&D portfolio analysis.
An important implication of our work is that when evaluating the risk of a
portfolio of risky R&D opportunities, it is not sufficient to merely examine
the risk-return properties between projects. It is also important to determine
the presence of conditional investment decisions before drawing conclusions
on how effective a project will be at reducing the risk of the portfolio. Fur-
thermore, policy makers may need to change their selection criteria over time.
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As companies mature and the need for conditional financing disappears along
with uncertainty, diversification of succesful projects becomes more important
in the future.
Extending the model in several ways facilitates the analysis of portfolio risk
under more specific circumstances. As we have shown, one can easily con-
struct a portfolio with projects that differ in volatility, time to maturity and
moneyness. It is also possible to compound several options when additional
parameters (such as success probabilities) are known. Using Appendix A, it is
easy to extend the analysis to a large portfolio, with each project having its
own distinct features such as the required investment outlay, estimated date
of completion and volatility of market value.
Applying our model in real-world case studies may yield interesting results in
the future. The simulation procedure remains the same for several underlying
stochastic processes and may include other case-specific properties such as
mean reversion, barriers or autocorrelation. It is also possible to account for
synergies on the cost side. To explore these directions, however, and to com-
pare empirical results with our framework, real-life data is needed to provide
realistic input parameters. Our study demonstrates the complexity of options
in a portfolio context, but when additional information on project parame-
ters is available to tailor the model to a specific problem, our framework can
be helpful in formulating and assessing research and development policy by
public and private parties.
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Appendix A: Explicit Derivation of Main Results
To examine the variance of a risky R&D portfolio more closely, we will present
an analytical treatment of our theoretical framework to convey what happens
when the correlation is perfectly positive, negative or absent. Because of the
nature of options (caused by the the max operator), the variance of a single
call option consists of two properly weighted variances: one variance for the
case in which the call value is positive  which we will denote by V ar(c+) 
and one for the case in which the outcome is zero:
V ar(max[V −X, 0]) = w1V ar(V −X) + w2V ar(0) = w1V ar(c+) (9)
where w1 and w2 are the appropriate weights, V is the project's value and X
the cost of investment. The key to an analytical derivation of the variances is
recognizing the outcome possibilities that exist in each of the three correla-
tion scenarios, and constructing a single variance from there, using a variance
decomposition formula that is defined as
V ar(A) = E[V ar(A|B)] + V ar(E[A|B]) (10)
We will consider a portfolio of two simple investment opportunities (calls) that
are exactly equal to each other. Both require an investment X that is assumed
to be equal to the expected value of the project (for ease of notation, we drop
the subscript i that we introduced in Section 3.1):
X1 = X2 = X = E[VT ] (11)
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As a consequence, for at the money options, each call will be distributed
around E[VT ]:
Pr(VT > X|X = E[VT ]) = Pr(ε > 0) = 0.5; ε ∼ N(0, 1) (12)
Furthermore, since both calls are identical, we know that the probability of
being in the money is equal for both calls i, j:
Pr(Vi,T > X) = Pr(Vj,T > X) (13)
The cases of perfectly positive, negative or absent correlation differ only in
the correlation that exist between two projects, and each will yield a differ-
ent expression for the portfolio variance, as expressed in terms of the option
components' variance in equation (9).
Perfectly Positively Correlated Projects
For ρ = 1, either both calls are in the money or both calls are out of the
money. This means that the portfolio consists of two possible outcomes:
Pf = (c+1 + c
+
2 |V1 > X, V2 > X) + (0|V1 < X, V2 < X)
Because of equation (12) and equation (13), each outcome is equally likely. In
this case (denoting the positive part of the portfolio as pf+ and the negative
as pf−), the variance composites on the right-hand side are:
29
V arpf+ =V ar(2c
+|V > X) = 4× V ar(c+|V > X)
V arpf− =0
Furthermore, we know that E[pf+] = 2E[c+] since both projects are identical.
From equation (10), it follows that the portfolio variance is:
V ar(pf |ρ = 1)= 4V ar(c
+) + 0
2
+
(2E[c+]− E[c+])2 + (0− E[c+])2
2
=2× V ar(c+) + E[c+]2
Perfectly Independent Projects
For ρ = 0, we know from equation (12) and equation (13) that each option
can be in the money or out of the money with equal probability. In this case,
we can therefore distinguish four possible outcomes :
Pf =(V1 −X|V1 > X, V2 < X)
+ (V2 −X|V1 < X, V2 > X)
+ (V1 −X + V2 −X|V1 > X, V2 > X)
+ (0|V1 < X, V2 < X)
The variance of the first two terms on the right hand side is equal to V ar(c+),
and the expected value for both is E[c+]. Since the non-linear payoff is ac-
counted for in the last term, we can use Markowitz's equation to find the
variance of the third term, which is simply the sum of the variances V ar(c+1 )
and V ar(c+2 ) because ρ = 0. Furthermore, we know that the expected value of
this term is equal to the sum of the expected values E[c+1 ]and E[c
+
2 ]. It follows
from equation (10) that
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V ar(Pf |ρ = 0)= V ar(c
+) + V ar(c+) + 2var(c+) + 0
4
+
0 + 0 + (2E[c+]− E[c+])2 + (0− E[c+])2
4
=V ar(c+) + 0.5(E[c+])2
This is exactly half of the variance found at ρ = +1, a finding that corresponds
with the simulation results.
Perfectly negatively correlated projects
For ρ = −1 and at the money options, we know that either one call or the
other is in the money. Yet since both projects can never jointly be in or out of
the money at ρ = −1, this simply means that the variance is equal to either
the variance of one call, or that of the other. More precisely, we can state that:
Pf =(c+1 |V1 > X, V2 < X) + (c+2 |V1 < X, V2 > X)
= c+1 = c
+
2 = c
+
The last line follows from the observation that the calls are identical under
the given conditions. It follows directly that
V ar(Pf |ρ = −1) = V ar(c+)
This demonstrates why in our results, the variance of a perfectly negatively
correlated portfolio doesn't go to 0% in the limit but is of a magnitude be-
tween zero and the variance at ρ = 0. Indeed, diversification under these
circumstances does not permit risk to be diversified away.
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Appendix B: How to Generate Random Samples from a Mul-
tivariate Normal Distribution
When a third stock enters our model, a third sample is drawn; ρ13 and ρ23
need to be defined in such a manner that the variances and covariance are
consistent. For instance, if asset 1 and asset 2 strongly move together as well
as asset 1 and 3 (that is, the correlations ρ12 and ρ13 are highly positive), then
the relation between asset 2 and 3 needs to be positive (that is, ρ23 needs to
have a high positive value) as well. If we require 3 correlated samples from
normal distributions, the required samples are defined as follows:
ε1=α11x1 (14)
ε2=α21x1 + α22x1 (15)
ε3=α31x1 + α32x1 + α33x1
The Choleski decomposition procedure is used to create a consistent corre-
lation structure, and is appropriate since we assume the disturbances to be
multivariate normally distributed. The procedure starts by setting α11 = 1
and requires α21 to be chosen such that α21α11 = ρ21 and α
2
21 + α
2
22 = 1. This
yields
α21 = ρ21 (16)
and
α22 =
√
1− ρ221 (17)
For the third sample, α31 is to be chosen such that α31α11 = ρ31, yielding
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α31 = ρ31. α32 is then to be chosen such that
α31α21 + α32α22 = ρ32, (18)
leading to
α32 =
ρ32 − ρ12ρ13√
1− ρ212
(19)
We conclude by the requirement that
α231 + α
2
32 + α
2
33 = 1, (20)
leading to
α33 =
√√√√√1− ρ213 − (ρ23 − ρ212ρ213√
1− ρ212
)2 (21)
We can simply generalize this case to n by expanding the Choleski matrix in
equation (15), for example to
ε4 = α41x1 + α42x2 + α43x3 + α44x4 (22)
and repeat this procedure. As the number of projects increases, however, cor-
relations need to be chosen with more and more care. Take the example of
a single pharmaceutical drug. If we want to simulate two additional projects
that both are correlated to this drug ρ12 = ρ13 = −0.9, then the additional
projects need to be positively correlated. More specifically, if we let the third
variable enter the simulation, it must satisfy
α231 + α
2
32 + α
2
33 = 1 (23)
33
or
α233 =
√
1− α231 − α232 =
√
1− 0.92 − α232 > 0. (24)
Hence, the Choleski-variable α232 must not be larger than (1 - 0.81 = ) 0.19
and
−
√
0.19 5 α32 5
√
0.19. (25)
Using this condition in the equation (18), we find the following range:
0.62 = 0.90× 0.90− 0.19× 0.19 ≤ ρ23 ≤ 0.90× 0.90 + 0.19× 0.19 = 0.88
If a fourth project enters the story and ρ14 = ρ12 = ρ13 = −0.9, it is required
that
α244 =
√
1− α241 − α242 − α243 =
√
1− 0.92 − α242 − α243 > 0
and, similarly to equation (25), that
−α22 ≤ α42 + α43 ≤ α22,
meaning that α42 + α43 are subject to the same constraint as was α32. Thus,
any new simulation variable is subject to all previous constraints, plus a
new constraint. For instance, if we choose ρ42 = ρ32(so that α42 = α32 and
α41, α42, α43 = α31, α32, α33), it must be true that
α44 =
√
1− α241 − α242 − α243 =
√
1− 0.81− 0.19− α243 > 0
and the fourth project needs to be uncorrelated with the others for consistency.
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Figure 1. Simulated Risk for Two Identical Investment Opportunities
Using portfolio variance as a measure for risk, the cumulative variance of two
simulated call options changes along with the correlation between the underly-
ing values. Using Equation (8) for calculating portfolio risk would be naive, as
it neglects option characteristics. The correct portfolio risk is graphed by the
variance of the sum of option values (values are obtained through simulation
and not reported); portfolio risk is normalized by dividing over the summed
variance of two independent calls. The correct variance develops similar to
naive variance, but is compressed towards the horizontal line, i.e. portfolio
variance when projects are independent (ρ = 0). Simulation parameters (no
dividend payments are made) are set as follows:
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Number of trials: R = 50, 000 Number of options: n = 2
Investment: X1 = X2 = 25 Project volatility: σ1 = σ2 = 25%
Project market value:V1 = V2 = 20 Discount rate: r = 20%
Time to completion: T = 18 months
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Figure 2. Sensitivity Analysis of Simulation Results
Number of trials: R = 50, 000 Number of options: n = 2
Investment: X1 = X2 = 25 Project volatility: σ1 = σ2 = 12.5%
Project market value:V1 = V2 = 20 Discount rate: r = 20%
Time to completion: T = 18 months
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Number of trials: R = 50, 000 Number of options: n = 2
Investment: X1 = X2 = 25 Project volatility: σ1 = 20%, σ2 = 30%
Project market value:V1 = V2 = 20 Discount rate: r = 20%
Time to completion: T = 18 months
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Number of trials: R = 50, 000 Number of options: n = 2
Investment: X1 = X2 = 25 Project volatility: σ1 = σ2 = 25%
Project market value:V1 = V2 = 25 Discount rate: r = 20%
Time to completion: T = 18 months
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Number of trials: R = 50, 000 Number of options: n = 2
Investment: X1 = X2 = 25 Project volatility: σ1 = σ2 = 25%
Project market value:V1 = V2 = 30 Discount rate: r = 20%
Time to completion: T = 18 months
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